WallStreetZenWallStreetZen

NASDAQ: EVO
Evotec Se Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their EVO stock forecasts and price targets.

Forecast return on equity

Is EVO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is EVO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

EVO revenue forecast

What is EVO's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$989.8M
Avg 2 year Forecast
$1.2B
Avg 3 year Forecast
$1.4B

EVO vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
EVO$5.23N/AN/A
AMRX$6.05$7.31+20.88%Strong Buy
AMPH$41.00$61.50+50.00%Buy
SUPN$30.26$41.00+35.49%Strong Buy
AVDL$17.66$23.67+34.01%Strong Buy
View Top Pharmaceutical Stocks

Evotec Se Stock Forecast FAQ

What is EVO's revenue growth forecast for 2024-2026?

(NASDAQ: EVO) Evotec Se's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Evotec Se's revenue in 2024 is N/A.On average, 2 Wall Street analysts forecast EVO's revenue for 2024 to be $175,381,099,279, with the lowest EVO revenue forecast at $171,653,997,322, and the highest EVO revenue forecast at $179,108,201,236. On average, 2 Wall Street analysts forecast EVO's revenue for 2025 to be $208,585,706,205, with the lowest EVO revenue forecast at $203,022,960,024, and the highest EVO revenue forecast at $214,148,452,387.

In 2026, EVO is forecast to generate $245,572,342,667 in revenue, with the lowest revenue forecast at $245,572,342,667 and the highest revenue forecast at $245,572,342,667.

If you're new to stock investing, here's how to buy Evotec Se stock.

What is EVO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: EVO) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of N/A.

What is EVO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: EVO) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.